171 related articles for article (PubMed ID: 34835009)
1. Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein.
Tan TH; Patton E; Munro CA; Corzo-Leon DE; Porter AJ; Palliyil S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835009
[TBL] [Abstract][Full Text] [Related]
2. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
3. Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.
Barh D; Tiwari S; Gabriel Rodrigues Gomes L; Weener ME; Alzahrani KJ; Alsharif KF; Aljabali AAA; Tambuwala MM; Lundstrom K; Hassan SS; Serrano-Aroca Á; Takayama K; Ghosh P; Redwan EM; Silva Andrade B; Soares SC; Azevedo V; Uversky VN
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696358
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway.
Xu H; Akinyemi IA; Chitre SA; Loeb JC; Lednicky JA; McIntosh MT; Bhaduri-McIntosh S
Virology; 2022 Mar; 568():13-22. PubMed ID: 35066302
[TBL] [Abstract][Full Text] [Related]
5. Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites.
Fam MS; Sedky CA; Turky NO; Breitinger HG; Breitinger U
Sci Rep; 2023 Apr; 13(1):5328. PubMed ID: 37005439
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
7. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
[TBL] [Abstract][Full Text] [Related]
8. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
[TBL] [Abstract][Full Text] [Related]
9. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress.
Chen D; Zheng Q; Sun L; Ji M; Li Y; Deng H; Zhang H
Dev Cell; 2021 Dec; 56(23):3250-3263.e5. PubMed ID: 34706264
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 ORF3a-Mediated NF-κB Activation Is Not Dependent on TRAF-Binding Sequence.
Busscher BM; Befekadu HB; Liu Z; Xiao TS
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005906
[TBL] [Abstract][Full Text] [Related]
11. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
[TBL] [Abstract][Full Text] [Related]
12. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation.
Miao G; Zhao H; Li Y; Ji M; Chen Y; Shi Y; Bi Y; Wang P; Zhang H
Dev Cell; 2021 Feb; 56(4):427-442.e5. PubMed ID: 33422265
[TBL] [Abstract][Full Text] [Related]
13. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
14. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
[TBL] [Abstract][Full Text] [Related]
17. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells.
Ren Y; Shu T; Wu D; Mu J; Wang C; Huang M; Han Y; Zhang XY; Zhou W; Qiu Y; Zhou X
Cell Mol Immunol; 2020 Aug; 17(8):881-883. PubMed ID: 32555321
[No Abstract] [Full Text] [Related]
18. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).
Boshuizen RS; Marsden C; Turkstra J; Rossant CJ; Slootstra J; Copley C; Schwamborn K
MAbs; 2014; 6(6):1415-24. PubMed ID: 25484047
[TBL] [Abstract][Full Text] [Related]
19. In silico investigation of the viroporin E as a vaccine target against SARS-CoV-2.
Rouka E; Gourgoulianis KI; Zarogiannis SG
Am J Physiol Lung Cell Mol Physiol; 2021 Jun; 320(6):L1057-L1063. PubMed ID: 33822639
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
